PRESS RELEASE published on 09/09/2024 at 22:56, 2 months 13 days ago Attestation du responsable du Rapport financier semestriel 2024 Déclaration de la personne responsable du rapport financier intermédiaire pour le semestre écoulé conforme aux normes IFRS, présentant une image fidèle de la société Déclaration Rapport Financier Normes IFRS Semestre Personne Responsable
PRESS RELEASE published on 09/09/2024 at 22:53, 2 months 13 days ago Rapport des CAC sur l'information financière semestrielle 2024
PRESS RELEASE published on 09/09/2024 at 22:43, 2 months 13 days ago Rapport CAC sur l'information financière semestrielle 2024
BRIEF published on 09/09/2024 at 22:40, 2 months 13 days ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:40, 2 months 13 days ago ABIVAX présente ses résultats semestriels 2024 Résultats Semestriels Abivax Cybersécurité Contrôle Interne Défaillances
PRESS RELEASE published on 09/09/2024 at 22:35, 2 months 13 days ago Lettre d'affirmation sur les comptes semestriels 2024 Lettre d'Affirmation Comptes Semestriels Consolidés IFRS de ABIVAX S.A. pour la période du 1 janvier 2024 au 30 juin 2024, validée par PwC Audit et Agili(3F) Audit IFRS Comptes Semestriels ABIVAX S.A. PwC Audit Agili(3F) Audit
PRESS RELEASE published on 09/09/2024 at 22:18, 2 months 13 days ago Rapport financier semestriel 2024
BRIEF published on 09/09/2024 at 22:06, 2 months 13 days ago Résultats financiers d'Abivax pour le premier semestre 2024 Résultats Financiers Biotechnologie Abivax Premier Semestre 2024 Mécanismes Immunitaires
BRIEF published on 09/09/2024 at 22:06, 2 months 13 days ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 2 months 13 days ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
Published on 11/22/2024 at 23:55, 19 hours 38 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 20 hours 3 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 20 hours 28 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 21 hours 3 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 1 day 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 16:55, 1 day 2 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:15, 1 day 3 hours ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 2 days 12 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
